{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:40:06Z","timestamp":1777876806710,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Hubei Chen Xiaoping Science and Technology Development Foundation Youth Special Funding Initiative","award":["CXPJJH124001-2445"],"award-info":[{"award-number":["CXPJJH124001-2445"]}]},{"name":"the Chinese Pharmaceutical Association Hospital Pharmacy department","award":["NO. CPA-Z05-ZC-2023002"],"award-info":[{"award-number":["NO. CPA-Z05-ZC-2023002"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>This study aimed to investigate the correlation between additional cytogenetic abnormalities (ACAs) at diagnosis and their clinical consequences in 337 Chinese chronic myeloid leukemia (CML) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Retrospective observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Response criteria were applied according to the European LeukemiaNet. Event-free survival (EFS) and progression-free survival (PFS) were analyzed. Independent predictors of PFS were assessed using Cox regression analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      At diagnosis, ACAs were identified in 41 patients (12.2%), with 24 exhibiting high-risk ACAs. Patients with high-risk ACAs showed significantly lower molecular response rates than those with low-risk ACAs or non-ACAs. Furthermore, patients with high-risk ACAs demonstrated diminished EFS (45.8% vs 76.5% vs 78.0%, respectively,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.03) and PFS (54.2% vs 94.1% vs 93.9%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) compared with those in the other groups. In the multivariate analysis, both the EUTOS long-term survival (ELTS) score and high-risk ACAs at diagnosis emerged as independent prognostic factors influencing the cumulative major molecular response (MMR) rate and PFS. Moreover, when stratified according to high-risk ACAs and ELTS score, patients with high-risk ACAs alongside an intermediate\/high ELTS score exhibited reduced MMR (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and inferior PFS rates (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0014).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>These findings underscore the importance of integrating cytogenetics-based risk assessments into CML management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251370504","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T11:43:12Z","timestamp":1757763792000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of additional cytogenetic aberrations at diagnosis of chronic phase chronic myeloid leukemia"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2257-6847","authenticated-orcid":false,"given":"Fang","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China"},{"name":"Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jundong","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Information and Data Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,13]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01204-6"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.0047"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0007"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-328294"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-015-2494-9"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2790"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01736-5"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.231"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0729-2"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0826-9"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690230"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003570"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011858"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-014-1685-9"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402813"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24943"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2023.107349"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282447"},{"issue":"9","key":"e_1_3_4_22_2","first-page":"2380","article-title":"Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention","volume":"108","author":"Shanmuganathan N","year":"2023","unstructured":"Shanmuganathan N, Wadham C, Shahrin N, et al. Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica 2023; 108(9): 2380\u20132395.","journal-title":"Haematologica"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251370504","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251370504","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251370504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:33:15Z","timestamp":1777588395000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251370504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":21,"alternative-id":["10.1177\/17588359251370504"],"URL":"https:\/\/doi.org\/10.1177\/17588359251370504","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9]]},"article-number":"17588359251370504"}}